The Experts below are selected from a list of 612 Experts worldwide ranked by ideXlab platform

Manuel Olivares - One of the best experts on this subject based on the ideXlab platform.

  • Bioavailability of Stabilised Ferrous Gluconate with Glycine in Fresh Cheese Matrix: a Novel Iron Compound for Food Fortification
    Biological trace element research, 2012
    Co-Authors: Fernando Pizarro, José Boccio, María J. Salgueiro, Manuel Olivares, Esteban Carmuega, Ricardo Weill, Sebastien Marque, Marine Frereux, Florence Noirt
    Abstract:

    Iron fortification of foods continues to be one of the preferred ways of improving the iron status of the population. Dairy product is a common product in the diet; therefore, it is a plausible vehicle for iron fortification. This study aims to investigate the bioavailability of Ferrous gluconate stabilised with glycine (FGSG) in a fresh cheese fortified with zinc. The iron bioavailability of fresh cheese fortified with either FGSG and with or without zinc and FGSG in aqueous solution and a water solution of Ferrous Ascorbate (reference dose) was studied using double radio iron (55Fe and 59Fe) erythrocyte incorporation in 15 male subjects. All subjects presented with normal values for iron status parameters. The geometric mean of iron bioavailability for the water solution of FGSG was 38.2 %, adjusted to 40 % from reference doses (N.S.). Iron bioavailability in fresh cheese fortified with Ca and Zn was 15.4 % and was 23.1 % without Zn, adjusted to 40 % from reference doses (N.S.). The results of the present study show that the novel iron compound Ferrous gluconate stabilised with glycine in a fresh cheese matrix is a good source of iron and can be used in iron fortification programmes.

  • iron absorption and iron status are reduced after roux en y gastric bypass
    The American Journal of Clinical Nutrition, 2009
    Co-Authors: Fernando Carrasco, Fernando Pizarro, Pamela Rojas, Juana Codoceo, Jorge Inostroza, Annabella Rebolledo, Karen Basfifer, Attila Csendes, Karin Papapietro, Manuel Olivares
    Abstract:

    Background: Iron deficiency and iron deficiency anemia are common in patients who undergo gastric bypass. The magnitude of change in iron absorption is not well known. Objective: The objective was to evaluate the effects of Roux-en-Y gastric bypass (RYGBP) on iron status and iron absorption at different stages after surgery. We hypothesized that iron absorption would be markedly impaired immediately after surgery and would not improve after such a procedure. Design: Anthropometric, body-composition, dietary, hematologic, and iron-absorption measures were determined in 67 severe and morbidly obese women [mean age: 36.9 6 9.8 y; weight: 115.1 6 15.6 kg, body mass index (BMI: in kg/m 2 ); 45.2 6 4.7] who underwent RYGBP. The Roux-en-Y loop length was 125‐150 cm. Determinations were carried out before and 6, 12, and 18 mo after surgery. Fifty-one individuals completed all 4 evaluations. Results: The hemoglobin concentration decreased significantly throughout the study (repeated-measures analysis of variance). The percentage of anemic subjects changed from 1.5% at the beginning of the study to 38.8% at 18 mo. The proportion of patients with low serum ferritin increased from 7.5% to 37.3%. The prevalence of iron deficiency anemia was 23.9% at the end of the experimental period. Iron absorption from both a standard diet and from a standard dose of Ferrous Ascorbate decreased significantly after 6 mo of RYGBP to 32.7% and 40.3% of their initial values, respectively. No further significant modifications were noted. Conclusion: Iron absorption is markedly reduced after RYGBP with no further modifications, at least until 18 mo after surgery. Am J Clin Nutr 2009;90:527‐32.

Fernando Pizarro - One of the best experts on this subject based on the ideXlab platform.

  • Bioavailability of Stabilised Ferrous Gluconate with Glycine in Fresh Cheese Matrix: a Novel Iron Compound for Food Fortification
    Biological trace element research, 2012
    Co-Authors: Fernando Pizarro, José Boccio, María J. Salgueiro, Manuel Olivares, Esteban Carmuega, Ricardo Weill, Sebastien Marque, Marine Frereux, Florence Noirt
    Abstract:

    Iron fortification of foods continues to be one of the preferred ways of improving the iron status of the population. Dairy product is a common product in the diet; therefore, it is a plausible vehicle for iron fortification. This study aims to investigate the bioavailability of Ferrous gluconate stabilised with glycine (FGSG) in a fresh cheese fortified with zinc. The iron bioavailability of fresh cheese fortified with either FGSG and with or without zinc and FGSG in aqueous solution and a water solution of Ferrous Ascorbate (reference dose) was studied using double radio iron (55Fe and 59Fe) erythrocyte incorporation in 15 male subjects. All subjects presented with normal values for iron status parameters. The geometric mean of iron bioavailability for the water solution of FGSG was 38.2 %, adjusted to 40 % from reference doses (N.S.). Iron bioavailability in fresh cheese fortified with Ca and Zn was 15.4 % and was 23.1 % without Zn, adjusted to 40 % from reference doses (N.S.). The results of the present study show that the novel iron compound Ferrous gluconate stabilised with glycine in a fresh cheese matrix is a good source of iron and can be used in iron fortification programmes.

  • iron absorption and iron status are reduced after roux en y gastric bypass
    The American Journal of Clinical Nutrition, 2009
    Co-Authors: Fernando Carrasco, Fernando Pizarro, Pamela Rojas, Juana Codoceo, Jorge Inostroza, Annabella Rebolledo, Karen Basfifer, Attila Csendes, Karin Papapietro, Manuel Olivares
    Abstract:

    Background: Iron deficiency and iron deficiency anemia are common in patients who undergo gastric bypass. The magnitude of change in iron absorption is not well known. Objective: The objective was to evaluate the effects of Roux-en-Y gastric bypass (RYGBP) on iron status and iron absorption at different stages after surgery. We hypothesized that iron absorption would be markedly impaired immediately after surgery and would not improve after such a procedure. Design: Anthropometric, body-composition, dietary, hematologic, and iron-absorption measures were determined in 67 severe and morbidly obese women [mean age: 36.9 6 9.8 y; weight: 115.1 6 15.6 kg, body mass index (BMI: in kg/m 2 ); 45.2 6 4.7] who underwent RYGBP. The Roux-en-Y loop length was 125‐150 cm. Determinations were carried out before and 6, 12, and 18 mo after surgery. Fifty-one individuals completed all 4 evaluations. Results: The hemoglobin concentration decreased significantly throughout the study (repeated-measures analysis of variance). The percentage of anemic subjects changed from 1.5% at the beginning of the study to 38.8% at 18 mo. The proportion of patients with low serum ferritin increased from 7.5% to 37.3%. The prevalence of iron deficiency anemia was 23.9% at the end of the experimental period. Iron absorption from both a standard diet and from a standard dose of Ferrous Ascorbate decreased significantly after 6 mo of RYGBP to 32.7% and 40.3% of their initial values, respectively. No further significant modifications were noted. Conclusion: Iron absorption is markedly reduced after RYGBP with no further modifications, at least until 18 mo after surgery. Am J Clin Nutr 2009;90:527‐32.

Kochupurackal P Mohanakumar - One of the best experts on this subject based on the ideXlab platform.

  • salicylic acid protects against chronic l dopa induced 6 ohda generation in experimental model of parkinsonism
    Brain Research, 2010
    Co-Authors: Anupom Borah, Kochupurackal P Mohanakumar
    Abstract:

    Abstract The present study evaluated the ability of salicylic acid (SA) to attenuate long-term l -DOPA-induced 6-hydroxydopamine (6-OHDA) formation in the striatum of mice, and to protect against the resulting dopaminergic neurotoxicity. The production of 6-OHDA from dopamine in vitro from Ferrous-Ascorbate-dopamine (FAD) hydroxyl radical ( • OH) generating system or in vivo in the striatum following prolonged administration of l -DOPA in mice were found to be significantly attenuated by SA. Intra-median forebrain bundle infusion of FAD, but not equivalent dose of Ferrous ion or dopamine individually, caused significant striatal dopamine depletion, which was blocked by SA administration. The dose- and time-dependent increase in the formation of 6-OHDA following l -DOPA treatment in the mouse striatum was synergistically enhanced to the systemic administration of the parkinsonian neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. SA treatment significantly attenuated the l -DOPA plus the parkinsonian neurotoxin-induced striatal 6-OHDA generation, and protected against striatal dopamine loss. The present study demonstrated a novel mode of dopaminergic neuroprotection by SA and its possible therapeutic implication in the treatment of Parkinson's disease.

  • melatonin inhibits 6 hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents
    Journal of Pineal Research, 2009
    Co-Authors: Anupom Borah, Kochupurackal P Mohanakumar
    Abstract:

    We tested the hypothesis that melatonin regulates formation of 6-hydroxydopamine (6-OHDA) in the brain and thereby protects animals from dopaminergic neurotoxicity and the development of parkinsonism in animals. Employing a Ferrous-Ascorbate-dopamine (FAD) hydroxyl radical ((*)OH) generating system, in the present study we demonstrate a dose-dependent attenuation of 6-OHDA generation by melatonin in vitro. Intra-median forebrain bundle infusion of FAD caused significant depletion of striatal dopamine (DA), which was blocked by melatonin. Per-oral administration of l-3,4-dihydroxyphenylalanine (L-DOPA) for 7 days caused a dose-dependent increase in the formation of 6-OHDA in the mouse striatum, which was increased synergistically by the systemic administration of the parkinsonian neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on the 7th day of L-DOPA treatment. Melatonin treatment significantly attenuated both the L-DOPA and MPTP-induced increases in the levels of striatal 6-OHDA, and protected against striatal DA depletion caused by the neurotoxin. These observations suggest a novel mode of melatonin-induced dopaminergic neuroprotection in two models of Parkinson's disease, and suggest the possible therapeutic use of this well-known antioxidant indoleamine neurohormone in parkinsonism.

Anupom Borah - One of the best experts on this subject based on the ideXlab platform.

  • salicylic acid protects against chronic l dopa induced 6 ohda generation in experimental model of parkinsonism
    Brain Research, 2010
    Co-Authors: Anupom Borah, Kochupurackal P Mohanakumar
    Abstract:

    Abstract The present study evaluated the ability of salicylic acid (SA) to attenuate long-term l -DOPA-induced 6-hydroxydopamine (6-OHDA) formation in the striatum of mice, and to protect against the resulting dopaminergic neurotoxicity. The production of 6-OHDA from dopamine in vitro from Ferrous-Ascorbate-dopamine (FAD) hydroxyl radical ( • OH) generating system or in vivo in the striatum following prolonged administration of l -DOPA in mice were found to be significantly attenuated by SA. Intra-median forebrain bundle infusion of FAD, but not equivalent dose of Ferrous ion or dopamine individually, caused significant striatal dopamine depletion, which was blocked by SA administration. The dose- and time-dependent increase in the formation of 6-OHDA following l -DOPA treatment in the mouse striatum was synergistically enhanced to the systemic administration of the parkinsonian neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. SA treatment significantly attenuated the l -DOPA plus the parkinsonian neurotoxin-induced striatal 6-OHDA generation, and protected against striatal dopamine loss. The present study demonstrated a novel mode of dopaminergic neuroprotection by SA and its possible therapeutic implication in the treatment of Parkinson's disease.

  • melatonin inhibits 6 hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents
    Journal of Pineal Research, 2009
    Co-Authors: Anupom Borah, Kochupurackal P Mohanakumar
    Abstract:

    We tested the hypothesis that melatonin regulates formation of 6-hydroxydopamine (6-OHDA) in the brain and thereby protects animals from dopaminergic neurotoxicity and the development of parkinsonism in animals. Employing a Ferrous-Ascorbate-dopamine (FAD) hydroxyl radical ((*)OH) generating system, in the present study we demonstrate a dose-dependent attenuation of 6-OHDA generation by melatonin in vitro. Intra-median forebrain bundle infusion of FAD caused significant depletion of striatal dopamine (DA), which was blocked by melatonin. Per-oral administration of l-3,4-dihydroxyphenylalanine (L-DOPA) for 7 days caused a dose-dependent increase in the formation of 6-OHDA in the mouse striatum, which was increased synergistically by the systemic administration of the parkinsonian neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on the 7th day of L-DOPA treatment. Melatonin treatment significantly attenuated both the L-DOPA and MPTP-induced increases in the levels of striatal 6-OHDA, and protected against striatal DA depletion caused by the neurotoxin. These observations suggest a novel mode of melatonin-induced dopaminergic neuroprotection in two models of Parkinson's disease, and suggest the possible therapeutic use of this well-known antioxidant indoleamine neurohormone in parkinsonism.

Fernando Carrasco - One of the best experts on this subject based on the ideXlab platform.

  • iron absorption and iron status are reduced after roux en y gastric bypass
    The American Journal of Clinical Nutrition, 2009
    Co-Authors: Fernando Carrasco, Fernando Pizarro, Pamela Rojas, Juana Codoceo, Jorge Inostroza, Annabella Rebolledo, Karen Basfifer, Attila Csendes, Karin Papapietro, Manuel Olivares
    Abstract:

    Background: Iron deficiency and iron deficiency anemia are common in patients who undergo gastric bypass. The magnitude of change in iron absorption is not well known. Objective: The objective was to evaluate the effects of Roux-en-Y gastric bypass (RYGBP) on iron status and iron absorption at different stages after surgery. We hypothesized that iron absorption would be markedly impaired immediately after surgery and would not improve after such a procedure. Design: Anthropometric, body-composition, dietary, hematologic, and iron-absorption measures were determined in 67 severe and morbidly obese women [mean age: 36.9 6 9.8 y; weight: 115.1 6 15.6 kg, body mass index (BMI: in kg/m 2 ); 45.2 6 4.7] who underwent RYGBP. The Roux-en-Y loop length was 125‐150 cm. Determinations were carried out before and 6, 12, and 18 mo after surgery. Fifty-one individuals completed all 4 evaluations. Results: The hemoglobin concentration decreased significantly throughout the study (repeated-measures analysis of variance). The percentage of anemic subjects changed from 1.5% at the beginning of the study to 38.8% at 18 mo. The proportion of patients with low serum ferritin increased from 7.5% to 37.3%. The prevalence of iron deficiency anemia was 23.9% at the end of the experimental period. Iron absorption from both a standard diet and from a standard dose of Ferrous Ascorbate decreased significantly after 6 mo of RYGBP to 32.7% and 40.3% of their initial values, respectively. No further significant modifications were noted. Conclusion: Iron absorption is markedly reduced after RYGBP with no further modifications, at least until 18 mo after surgery. Am J Clin Nutr 2009;90:527‐32.